This study used lower magnesium concentrations (0.3 mmol/L) in the dialysate for the magnesium group compared with 0.48 mmol/L in the calcium group to reduce the risk of hypermagnesaemia, whereas dialysate calcium was 1.50 mmol/L for both groups.
Blocking the NMDA receptor in neurons with APV (n=56; 25 μM), MK801 (n=65; 10 μM) and ifenprodil (n=52; 10 μM) in low magnesium conditions significantly reduced the rate of ROS production both 2 min and 10 min after omission of magnesium when compared with control.
Over the next four weeks, 7.8percentt of those receiving magnesium died compared with 10.3percentt of those injected with salt water, for a 24percentt reduction in fatal heart attacks.
There were no differences in delivery within 48 hours (7.6% magnesium sulfate compared with 8.0% nifedipine, P=.92), gestational age at delivery (35.8 compared with 36.0 weeks, P=.61), birth before 37 and 32 weeks (57% compared with 57%, P=.97, and 11% compared with 8%, P=.39), and episodes of recurrent preterm labor.
At low laser pulse frequencies the measured weight- % of magnesium decreased compared with the initial value of the untreated AZ31.
In addition, there seems to be a greater likelihood of clinical symptoms with a rapid decrease in serum magnesium concentration compared with a more gradual change.
Magnesium, when compared with amiodarone, has been found to be more effective in restoration of SR, while the two treatments are equally effective in rate control [ 73].
One Cochrane review that assessed magnesium sulphate for women with pre-eclampsia had previously shown a small increased risk of caesarean section for women receiving magnesium sulphate, compared with placebo/no treatment [ 4], as was suggested in this review.
Both treatment groups had significantly increased serum magnesium levels compared with the placebo arm, with the higher dose group suffering a greater number of adverse events such as diarrhoea, vomiting and dyspepsia.
The four randomised trials reporting on 'any adverse effects' of treatment, showed an absolute risk of 38% (2,521/6,642) for women exposed to antenatal magnesium sulphate compared with 8.5% (567/6,680) for women unexposed.
